Recap: NeoGenomics Q2 Earnings

 

Shares of NeoGenomics NEO were unchanged after the company reported Q2 results.

Quarterly Results

Earnings per share were up 75.00% year over year to ($0.01), which beat the estimate of ($0.06).

Revenue of $121,724,000 higher by 39.95% year over year, which beat the estimate of $118,160,000.

Guidance

The upcoming fiscal year's EPS expected to be between ($0.27) and ($0.23).

The upcoming fiscal year's revenue expected to be between $490,000,000 and $510,000,000.

Conference Call Details

Date: Aug 06, 2021

Time: 08:30 AM

ET Webcast URL: https://www.webcaster4.com/Webcast/Page/1219/42174

Recent Stock Performance

Company's 52-week high was at $61.57

Company's 52-week low was at $34.18

Price action over last quarter: Up 13.43%

Company Description

NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Pharma Services. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. The company generates revenue from Clinical Services.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!